NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

I recommend that you get in touch with Dr. Liau and/or Dr. Prins at UCLA. The trial that included DCVax-L along with poly-ICLC was not just for brain tumor patients who were diagnosed with Glioblastoma.

It also included all malignant Grade III and Grade IV brain tumors. That includes Glioblastoma and some Astrocytomas.



https://assets.researchsquare.com/files/rs-3287211/v1/570baff706a2ae91b1cc7e7a.pdf

Also, you can take a look at the preprinted trial results for this trial. You will see that the patients who were diagnosed with a Grade III Astrocytoma had very good survival results when treated with DCVax-L along with poly-ICLC:

https://assets.researchsquare.com/files/rs-3287211/v1_covered_72e8e045-4db9-40aa-b629-f4a452ce8b55.pdf?c=1695835180

Also, it is my opinion that when DCVax-L is initially approved in the US, Canada, UK, Germany and the rest of the EU, the initial approved label will include all malignant Grade III and Grade IV gliomas, including Glioblastoma and Astrocytoma:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173058182

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173061962